Investigational drug · Phase 2
LY4100511
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Plaque Psoriasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "LY4100511"
First trial start
2024
Oct 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY4100511", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "LY4100511" as an intervention, largest first.
- A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06602219 · 222 participants · Start Oct 25, 2024 · Primary completion Jul 24, 2025
Drug: LY4100511; Placebo · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Bryant, Arkansas; Beverly Hills, California · 58 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06937411 · 88 participants · Start Feb 13, 2023 · Primary completion Oct 30, 2023
Drug: LY4100511 · For: Healthy
Sites: Manchester, United Kingdom
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06311656 · 69 participants · Start Mar 19, 2024 · Primary completion Oct 4, 2024
Drug: LY4100511 (DC-853); LY4100511 (DC-853) and 3 more · For: Healthy
Sites: Cypress, California
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06345794 · 50 participants · Start Apr 3, 2024 · Primary completion Jun 18, 2024
Drug: LY4100511 (DC-853); Itraconazole and 2 more · For: Healthy
Sites: San Antonio, Texas
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06503679 · 49 participants · Start Jul 16, 2024 · Primary completion Dec 31, 2024
Drug: LY4100511 (DC-853) Dose 1; LY4100511 (DC-853) Dose 2 and 5 more · For: Healthy
Sites: Dallas, Texas
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06627088 · 24 participants · Start Aug 23, 2024 · Primary completion Dec 31, 2024
Drug: LY4100511 (DC-853); [14C]-LY4100511 (DC-853) Administered oral dose and 2 more · For: Healthy
Sites: Madison, Wisconsin
Eli Lilly and CompanyEli Lilly (LLY)
NCT06916143 · 1 participants · Start Apr 8, 2025 · Primary completion Apr 8, 2025
Drug: LY4100511; Rabeprazole · For: Healthy Participants
Sites: Miami, Florida; Knoxville, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.